BSI 045A
Alternative Names: BSI-045ALatest Information Update: 20 Dec 2023
Price :
$50 *
At a glance
- Originator Biosion
- Developer Biosion; Chia Tai Tianqing Pharmaceutical Group
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 20 Dec 2023 Phase-II clinical trials in Atopic dermatitis in China (Parenteral) before December 2023 (Biosion pipeline, December 2023)
- 01 Aug 2022 Biosion and Chia Tai Tianqing Pharmaceutical Group agree to co-develop BSI 045A for Atopic dermatitis (Biosion pipeline, August 2022)
- 01 Aug 2022 Phase-I clinical trials in Atopic dermatitis in China (Parenteral)